Bioanalytical approach to accelerate development efforts in the identification of compounds that can treat chlorine or sulfur mustard injuries
The new facility will provide an important boost to vaccine capacity in Africa
The product is synthetically developed as compared to the current process of drawing the same from blood plasma and is backed by a granted global patent
The acquisition expands Takeda’s immuno-oncology and innate immune cell therapy portfolio with novel platforms leveraging T cells for the potential treatment of solid tumours and haematological malignancies
Filing marks first protein-based vaccine submitted to MHRA for authorization
U.S. FDA has accepted the investigational new drug application for phase 1 clinical trial in non-Hodgkin’s lymphoma
Early-stage research suggests the potential to prevent and treat all dengue serotypes and builds on Johnson & Johnson's work to advance science against emerging and entrenched global public health threats
The company plans to submit the IND application by the end of 2021
It is a recombinant nanoparticle protein-based vaccine
Initiation of EBT-101 Phase 1/2 clinical trial expected later this year
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
